Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 29, 2010

EMD Millipore Licenses Tissue-Staining Method from Cleveland Clinic

  • EMD Millipore has obtained rights to a technique for protein research from Cleveland Clinic. The new method is intended to reduce the time required for staining tissue sections from 12 hours to 30 minutes.

    The technique was developed using Millipore's SNAP i.d.® Protein Detection System. Scientists at Millipore and Cleveland Clinic are in the process of validating the method for diverse tissue types and fixation protocols.

    “By reducing tissue analysis time to minutes, the SNAP i.d. system can increase research throughput and speed up protocol optimization, enabling researchers to make faster decisions about their results,” comments Don O’Neil, director of product management at Millipore.

    The SNAP i.d. system from Millipore uses vacuum to actively drive reagents through membrane-fixed tissue sections. This reportedly increases exposure of tissue antigens to blocking reagents, antibodies, and wash buffers. Traditional tissue staining involves mounting sections on glass slides and relies on diffusion for reagent permeation through the sections.

    EMD Millipore was born out of Merck KGaA’s $7 billion acquisition of Millipore. It was announced in March and completed in July. EMD Millipore is the life science division, combing Merck’s EMD Chemicals business in New Jersey with Millipore. It is known as Merck Millipore outside the U.S. and Canada.



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

Be sure to take the GEN Poll

Pharmacists and Prescription Drug Misuse Programs

Do you agree that pharmacists should make a greater effort to become more involved with prescription drug-monitoring programs?

More »